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Dermcidin expression in hepatic cells improves survival without
N-glycosylation, but requires asparagine residues
AG Lowrie*,1, SJ Wigmore1, DJ Wright1, ID Waddell2 and JA Ross1
1Tissue Injury and Repair Group, Chancellor’s Building, The University of Edinburgh Medical School, Royal Inf irmary of Edinburgh, 51 Little France
Crescent, Edinburgh, UK; 2Cardiovascular and Gastrointestinal Research Department, AstraZeneca, Mereside, Alderley Park, Macclesf ield SK10 4TG, UK
Proteolysis-inducing factor, a cachexia-inducing tumour product, is an N-glycosylated peptide with homology to the unglycosylated
neuronal survival peptide Y-P30 and a predicted product of the dermcidin gene, a pro-survival oncogene in breast cancer. We aimed
to investigate whether dermcidin is pro-survival in liver cells, in which proteolysis-inducing factor induces catabolism, and to determine
the role of potentially glycosylated asparagine residues in this function. Reverse cloning of proteolysis-inducing factor demonstrated
B100% homology with the dermcidin cDNA. This cDNA was cloned into pcDNA3.1þ and both asparagine residues removed
using site-directed mutagenesis. In vitro translation demonstrated signal peptide production, but no difference in molecular weight
between the products of native and mutant vectors. Immunocytochemistry of HuH7 cells transiently transfected with V5-His-tagged
dermcidin confirmed targeting to the secretory pathway. Stable transfection conferred protection against oxidative stress. This was
abrogated by mutation of both asparagines in combination, but not by mutation of either asparagine alone. These findings suggest that
dermcidin may function as an oncogene in hepatic as well as breast cells. Glycosylation does not appear to be required, but the
importance of asparagine residues suggests a role for the proteolysis-inducing factor core peptide domain.
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The first product of the dermcidin gene to be identified was
proteolysis-inducing factor (PIF), a novel cachectic factor that was
purified from a cachexia-inducing murine tumour and the urine
of weight-losing patients with pancreatic cancer (Todorov et al,
1996; Wigmore et al, 2000). Screening of tissues for PIF binding
demonstrated substantial binding only to skeletal muscle and liver
(unpublished observation), and we have investigated the effect of
PIF on liver cells. In primary hepatocytes and HepG2 cells, PIF was
found to activate the transcription factors NF-kB and STAT3,
resulting in the stimulation of IL-8, IL-6 and CRP production, and
the inhibition of transferrin production (Watchorn et al, 2001).
Proteolysis-inducing factor was also found to induce the expres-
sion of NF-kB, IL-6, IL-8, ICAM-1 and VCAM and the shedding
of syndecans in the liver endothelial cell line SK-HEP-1 and
human umbilical vein endothelial cells, but not in pulmonary
artery endothelial cells (Watchorn et al, 2002). These results are
consistent with a role as a cachectic factor. In addition, the roles of
ICAM-1, VCAM and syndecans in development, inflammation,
tissue repair and host defence (Collins et al, 1995; Attar et al, 1999;
Park et al, 1999; Zimmermann and David, 1999) suggested for the
first time that dermcidin may have a role in liver biology outwith
the cachectic process.
More recently, different proteolytic fragments have been
characterised, which all appear to be derived from the protein
encoded by the dermcidin gene. These fragments have different
roles and have been identified in different tissues. One fragment
is DCD-1, a proteolytically processed 47-amino-acid C-terminus
product of dermcidin secreted by eccrine sweat glands, which has
antimicrobial activity against a variety of pathogenic micro-
organisms (Schittek et al, 2001). The amino-acid sequence of DCD-
1 does not overlap with that of PIF. A second product is diffusible
survival evasion peptide (DSEP, or Y-P30), a neuronal survival
peptide identified in the medium of oxidatively stressed neuronal
cell lines (Cunningham et al, 1998). Y-P30 is a product of the same
region of dermcidin as the core peptide of PIF (Figure 1B).
Enzymatic degradation of the PIF glycoprotein has suggested
that the molecule consists of a peptide core of molecular weight
4000 Da, which is extensively N- and O-glycosylated to give an
apparent mass of 24 kDa (Todorov et al, 1997). This may be
essential to its function as a cachetic factor, as dermcidin
expression does not appear sufficient to induce cachexia (Monitto
et al, 2004). Similarly, deglycosylated PIF lacks proteolytic activity
in murine gastrocnemius muscle (Todorov et al, 1996, 1997), and
in our experiments it was the fully glycosylated PIF molecule that
influenced hepatic cell NF-kB and STAT3 activity and gene
expression (Watchorn et al, 2001, 2002). However, the PIF amino-
acid sequence lacks typical consensus N- and O-glycosylation sites
and the mechanism of glycosylation remains unknown.
The unglycosylated PIF amino-acid sequence is predicted to be
identical to that of Y-P30 (Todorov et al, 1996; Cunningham et al,
1998), and it is now believed that dermcidin may play a role in
carcinogenesis via the action of this peptide. Dermcidin has been
identified as a candidate oncogene in breast cancer and stable
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transfection has been shown to stimulate cell growth and inhibit
menadione-induced cell death, as assessed by cell counting (Porter
et al, 2003). Stable transfection of dermcidin has also been
demonstrated to improve the survival of neuronal cells subjected
to oxidative stress with H2O2 (Cunningham et al, 2002), and it is
feasible that these effects are due to the activity of Y-P30. The
mechanism by which this peptide improves survival appears to
involve a central, calcineurin-like phosphatase domain (Cunning-
ham et al, 1998). This domain contains one of the two possible N-
glycosylation sites of PIF and lies just seven amino acids from the
other.
In this study, we sought to investigate whether dermcidin
expression affected the survival of hepatic cells and to examine the
structural elements involved in this function. We also describe the
confirmatory cloning and sequencing of the dermcidin cDNA from
the PIF peptide sequence and the investigation of co-translational
processing of the nascent polypeptide in an in vitro translation
system.
MATERIALS AND METHODS
Computer searches
A computer search of the Lifeseq Foundation database (Incyte,
Cambridge, UK) was performed to identify alignments between the
20 known N-terminal amino acids of glycosylated PIF (Todorov
et al, 1996) and translated Incyte sequences. BLAST searches were
performed using the national library of medicine facility (http://
www.ncbi.nlm.nih.gov/). Post-translational modification was mod-
elled using SignalP (http://www.cbs.dtu.dk/services/SignalP/), Net-
O-Glyc (http://www.cbs.dtu.dk/services/NetOGlyc/) and Net-N-
Glyc (http://www.cbs.dtu.dk/services/NetNGlyc/).
PCR
PCR primers were designed to include the PIF/dermcidin sequence
from translation initiation to the final STOP codon, clamped 50
BamH1 and Kozak sequences added to the forward primer and
clamped 30 EcoRI sequences added to the reverse primer
(F¼CTCGGATCCGCCGCCATGAGGTTCATGACTCTCC, R¼CAG
AATTCCTGGGTATCATTTCTCAGCT) (TAGN, Newcastle,
UK). Reaction mixtures (25 ml) containing 0.75 ml 25 mM MgCl2,
2.5ml taq poly 10 buffer, 2.5 ml dNTPs, 1 mM forward and reverse
primers and 1 ml taq polymerase at a 1 in 5 dilution were made up
in nuclease-free water (all reagents from Promega, Poole, UK).
Proteolysis-inducing factor/dermcidin was then amplified from
cDNA derived from the G361 human melanoma cell line using a
standard cycle (951C for 5 min, followed by 35 cycles of 951C for
1 min, 561C for 1 min and 721C for 1 min, then 10 min at 721C)
(ECACC, Porton Down, UK). Samples were run on 1.4% agarose
gels, stained with ethidium bromide and visualised under UV
illumination.
RNA preparation and reverse transcription
RNA was prepared from cells cultured in six-well plates using
Trizol (Life Technologies, Paisley, UK) according to the manu-
facturer’s instructions. Samples were DNAse treated using RQ1
DNAse (Promega) according to the manufacturer’s instructions.
Reverse transcription was performed in 20 ml reactions containing
10ml of RNA sample plus 10 ml of RT mix (4 ml 25 mM MgCl2,
Figure 1 (A) Homology between the PIF clone 607227, DSEP and dermcidin cDNAs. Clone 607227 was identified by screening the Lifeseq Foundation
database (Incyte) for sequences which, when translated, showed a high degree of homology to the PIF amino-acid sequence. A high degree of homology
between the translated and untranslated sequences of the three cDNAs can also be seen to exist. The 330 bp ORF is 100% homologous in all sequences.
(B) Amino-acid homology between PIF, Y-P30 and dermcidin. Proteolysis-inducing factor shares all but three amino acids with the predicted dermcidin
protein and mismatches may be the result of sequencing artefact resulting in the conversion of cysteine to serine (Todorov et al, 1996). Similarly, only the
two unidentifiable amino acids of Y-P30 (Cunningham et al, 1998) do not match with the predicted dermcidin protein. These results are subsequently
consistent with both the PIF core peptide and Y-P30 arising from the dermcidin protein. The sequence of the dermcidin peptide DCD-1 does not overlap
with that of Y-P30 or the PIF core peptide. (C) Diagram of the PIF protein arrangement showing sites of signal peptide, Y-P30 and DCD-1 cleavage.
Asparagine and serine residues, which are the only potential N- and O-glycosylation sites, respectively, are underlined and can be seen to lie in the Y-P30
sequence, with the exception of the four serine residues of DCD-1. The Y-P30 and DCD-1 sequences were derived as described (Cunningham et al, 1998;
Schittek et al, 2001). The signal peptide sequence and N- and O-glycosylation sites were derived by computer modelling using SignalP, Net-N-Glyc and Net-
O-Glyc, respectively.
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2 ml reverse transcription 10 buffer, 2 ml dNTP mixture, 1 ml
oligo(dT)15 primer, 0.5 ml AMV reverse transcriptase and 0.5 ml
recombinant RNasin ribonuclease inhibitor, all from Promega).
Samples were then incubated in a thermal cycler (PHC-3, Techne)
for 1 h at 421C, followed by 5 min at 991C.
Cloning
Bands of the appropriate size were excised from gels and purified
using a gel purification kit (Qiagen, Crawley, UK). Samples and
vectors (pcDNA3.1þ and pcDNA3.1V5-His, Invitrogen) were
double digested with BamH1 and EcoR1 for 16 h at 371C and
digestion byproducts removed by gel purification. Directional
ligation was performed in 10 ml reactions containing 1 ml T4 DNA
ligase, 1 ml 10 ligation buffer (Promega), 100 ng insert and the
appropriate amount of vector to give 3 : 1, 1 : 1 and 1 : 3 molar
ratios of insert to vector. Ligated vectors were then transformed
into TOP10 Escherichia coli (Invitrogen) as per the manufacturer’s
instructions and plated on LB agar plus 50 mg ml1 ampicillin
(Sigma, Poole, UK). Colonies were screened for insert incorpora-
tion by PCR and incubated in 3 ml LBþ 50 mg ml1 ampicillin
minibroths overnight at 371C with agitation. Plasmids were
prepared by alkaline lysis and ethanol precipitation. All plasmids
were sequenced prior to large-scale culture and purification using
an Endofree plasmid maxi kit (Qiagen).
Site-directed mutagenesis
Site-directed mutagenesis was performed using a Quikchange II kit
(Stratagene, Amsterdam, the Netherlands) according to the
manufacturer’s instructions. Primers used were: N32Q F-CCAG-
GATCGGGGCAGCCTTGCCATGAAGC, N32Q R- GCTTCATGG-
CAAGGCTGCCCCGATCCTGG, N44Q F-CAGCAGCTCAAAAGGA
ACAGGCAGGTGAAGACCCAG and N44Q R- CTGGGTCTTCACC
TGCCTGTTCCTTTTGAGCTGCTG. Double N32Q, N44Q mutants
were created by mutation of the pcDNA3.1þPIF N32Q plasmid
with N44Q primers.
In vitro translation
In vitro translation was performed using a rabbit reticulocyte
system (Promega) according to the manufacturer’s instructions.
Radioisotopes used were 35S-methionine, 14C-leucine and 35S-
cysteine (ICN Pharmaceuticals Ltd, Basingstoke, UK). In selected
experiments, reactions were supplemented with 1.2 ml canine
pancreatic microsomal membranes (CPMM) (Promega). Samples
were run on 10–20% tris-tricine gels (Biorad, Hemel Hempstead,
UK) at 70 V on ice and visualised by fluorography.
Transfection and cell culture
Plasmids were transfected into the HuH7 cell line (ECACC) using
Fugene (Roche Applied Science, Lewes, UK) according to the
manufacturer’s instructions. Stable transfectants were selected by
culture in 600mg ml1 G418 (Sigma). Cells were maintained at 371C
in 5% CO2 in air atmosphere in Dulbecco’s modified Eagle’s
medium with 10% FCS, 50 U ml1 penicillin, 50 mg ml1 strepto-
mycin and 2 mmol glutamine (Gibco-BRL, Paisley, UK).
Assessment of cell survival following oxidative stress
Cells were plated in 96-well plates (Gibco) at 1.5 104 cells per well
and cultured overnight prior to the induction of oxidative stress by
the addition of 75 mU ml1 glucose oxidase (Sigma) for 2 h. The
medium was then replaced and cells incubated under standard
conditions for 4 h. Cell survival was then assessed by MTT assay.
In all, 10 ml of 5 mg ml1 MTT was added to each well and
incubated for 4 h at 371C. Then, 100 ml per well of 10% SDS, pH 3.0
was added and plates were incubated overnight at 371C prior to
reading at 570 nm on an Assayzap plate reader.
Flow cytometry
For flow cytometry experiments cells were seeded in six-well plates
at 1 106 per well. Following glucose oxidase treatment, cells and
their culture medium were harvested, pelleted and washed twice
by resuspension in PBS and centrifugation at 1500 g for 5 min.
Annexin V/PI flow cytometry was performed using a Bender
Medsystems kit according to the manufacturer’s instructions
(Bender Medsystems, Vienna, Austria). Cleaved caspase 3 flow
cytometry was performed using the cleaved caspase-3 (Asp175)
(5A1) rabbit monoclonal antibody (Cell Signaling, Hitchin, UK)
according to the manufacturer’s instructions. Flow cytometry
using the BOB78 antibody at 1 in 100 and control antibody, also of
IGM isotype (Sigma), was performed as described previously (Hart
et al, 2000). The secondary antibody used was sheep anti-mouse
IgG FITC (Dako, Ely, UK). Samples were analysed using a Coulter
Epics XL flow cytometer.
Immunocytochemistry
Cells were seeded at 2 104 cells per well in eight-well chambered
slides and allowed to settle overnight prior to glucose oxidase
treatment. For V5-His visualisation, cells were treated with 5 mM
monensin (Sigma) and visualised directly using FITC-labelled anti-
V5 His antibody (Invitrogen, Paisley, UK). For assessment of cell
death with annexin V, BOB78 and anti-cleaved caspase 3 cells were
treated with glucose oxidase and dead cells harvested from the
medium. These were then cytospun onto positively charged slides
at 300 rpm for 3 min.
Annexin V staining was performed by incubation of cytospins
for 5 min at room temperature in 50 ml of annexin binding buffer
containing 1.25 ml annexin V and 1.25 ml propidium iodide (Bender
Medsystems).
BOB78 staining was performed by blocking for 1 h at room
temperature in 20% rabbit serum, then staining for 1 h at room
temperature with BOB78 diluted 1/100 in PBS. Slides were washed
in PBS, then incubated at room temperature for 30 min with
secondary rabbit anti-mouse FITC-conjugated immunoglobulins
(Dako) diluted 1/100 in PBS. Cells were fixed in 3% paraformalde-
hyde for 5 min and mounted in fluorescent mounting medium
(Dako) prior to visualisation on a Leica DMIRB fluorescent
microscope (Wetzlar, Germany).
RESULTS
Cloning and structural homology of PIF
We obtained the cDNA for dermcidin through the reverse cloning
of PIF. A search of the Lifeseq Foundation database identified
a single clone, no. 607227, which, when translated, showed 90%
similarity to the 20 N-terminal amino acids of the PIF core peptide
(Figure 1A). The sequence was registered with Genbank (accession
number AY590150). PCR of the coding area of this sequence
allowed confirmatory cloning and sequencing from G361 cDNA.
A BLAST search of the human genome database localised PIF
to chromosome 12q13 and identified B100% homology with the
dermcidin gene (AF144011) and DSEP (AY044239), the sequence
encoding Y-P30. Modelling with Signal-P suggested a high
likelihood that a signal peptide was cleaved between A19 and
Y20 and that the protein was likely to be targeted to the secretory
pathway (Figure 1C). Net-N-Glyc did not demonstrate typical
Asn– X– Ser/Thr N-glycosylation sites in the PIF/dermcidin
amino-acid sequence. A search of all potential N-glycosylation
sites revealed N-glycosylation potentials of 0.766 and 0.6294 for
N32 and N44, the former of which conforms to a previously
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described atypical N-glycosylation site (Sato et al, 2000). Net-O-
Glyc modelling did not reveal any Ser/Thr sites meeting the
threshold for O-glycosylation. A map of the predicted nascent
polypeptide translated from the dermcidin gene is shown in
Figure 1B.
Creation and site-directed mutagenesis of expression
vectors
In order to study the expression and co-translational modification
of PIF/dermcidin, the full-length cDNA was directionally cloned
into the mammalian expression vector pcDNA3.1þ . Site-directed
mutagenesis was then employed to remove the asparagine residues
of the calcineurin-like phosphatase domain. The mutants created
were the asparagine to glutamine substitutions N32Q and N44Q
and the double asparagine to glutamine substitution N32Q N44Q.
All plasmid sequences were confirmed by direct sequencing.
In vitro translation of pcDNA3.1þPIF
To investigate co-translational processing of native and mutant
DCD, in vitro translation using a coupled T7 RNA polymerase/
rabbit reticulocyte lysate system and canine pancreatic micorsomal
membranes was performed. Translation of pcDNA3.1þPIF in the
presence of 35S-methionine gave an unprocessed product of 11 kDa
(Figure 2A). Co-translational processing, in the presence of
CPMM, produced a cleavage product of approximately 2.5 kDa
(Figure 2B). In vitro translation of N32Q, N44Q and N32Q N44Q
mutant vectors with 35S-cysteine resulted in products of molecular
weight identical to wild-type PIF/dermcidin (Figure 2C).
Targeting of PIF/dermcidin to the secretory pathway
In order to study subcellular localisation, the PIF/dermcidin cDNA
was cloned into the pcDNA3.1þ V5 His vector and transiently
transfected into HuH7 cells. Anti-V5 His immunocytochemistry
of these cells demonstrated staining only after treatment with
monensin, an inhibitor of intracellular protein transport (Figure 3).
Generation of stable transfectants
PCR demonstrated that untransfected, unstimulated HuH7 cells
did not express PIF/dermcidin (Figure 4A). However, following
prolonged culture, a low level of DCD expression was observed
(Figure 4B). Following transfection and selection, strong expres-
sion was observed (Figure 4B). The expression observed in empty
pcDNA3.1þ transfected cells raised the possibility that expression
may be induced by the transfection and selection process.
However, anti-neomycin phosphotransferase Western blotting
confirmed the activity of pcDNA3.1þ ’s constitutive CMV
promoter region in all transfected cells (Figure 4D). This promoter
also drives the multiple cloning site. All aspects of transfection
which may affect cell behaviour, except dermcidin overexpression
from the vector, are subsequently controlled for.
Analysis of HuH7 cell response to oxidative stress
Empty vector-transfected cells were subjected to oxidative stress
using glucose oxidase. Treatment for 2 h with 75 mU ml1 glucose
oxidase resulted in a decrease in survival of 66% on MTT assay
(Figure 5A). On flow cytometry, forward- and side-scatter gated
82% of untreated cells as live and 18% as dead (Figure 5B and C).
Glucose oxidase treatment decreased the live gate to 29%, a 65%
reduction (Figure 5D). There was a commensurate increase in the
dead gate to 71%. Glucose oxidase-treated HuH7 cells did not stain
with anti-cleaved caspase 3 antibodies. Analysis of annexin V
staining patterns revealed that untreated, 4% stained with annexin
only, 7% with PI only, 11% with both and 79% with neither
(Figure 6A). When treated with glucose oxidase, 14% stained with
annexin only, 9% with PI only, 58% with both and 19% with
neither. On staining of cells with the BOB78 antibody, a surface
marker of apoptosis (Hart et al, 2000), 8% stained with BOB78 only
in the untreated sample, 6% with PI only, 6% with both and 80%
with neither (Figure 7A). On glucose oxidase treatment, 12%
stained with BOB78 only, 18% with PI only, 45% with both and
253% with neither (Figure 7A). Immunocytochemistry with both
annexin V and BOB78 (Figures 6B and 7B) also revealed a
Empty
CPMM concentration
Vector
CPMM – + – + – + – +
PIF N32Q N44Q N32QN44Q
PIF
61 kDa
11 kDa
19 kDa
17 kDa
11 kDa
11 kDa
6 kDa
3 kDa
Luciferase
0 0.3 0.6 0.9
A
B
C
Figure 2 In vitro translation of pcDNA3.1þ PIF. (A) Gel of 35S-
methionine labelled in vitro translation reaction using the coupled T7 RNA
poymerase and rabbit reticulocyte lysate system. DNA templates used
were from left to right, pcDNA3.1þ (empty vector), pcDNA3.1þ PIF and
luciferase. Translation of PIF from the pcDNA3.1þ PIF plasmid resulted in
an 11 kDa product (middle lane). The 61 kDa product of the luciferase
control gene can be seen in the right-hand lane. (B) Addition of CPMM
resulted in the dose-dependent production of a 2.5 kDa band in translation
reactions in which pcDNA3.1þ PIF was used as a template. (C)
Translation of the N32Q, N44Q and N32Q N44Q mutants in the
presence of 1.2 ml per reaction of CPMM resulted in products of molecular
weight identical to the translation product of wild-type PIF/dermcidin.
DAPI FITC Merge
Figure 3 Immunocytochemistry of V5-His-tagged PIF transiently trans-
fected into HuH7 cells in the pcDNA3.1þV5His PIF vector. Following
transfection, cells were treated with the inhibitor of glycoprotein secretion
monensin, fixed and co-stained with an FITC-labelled anti-V5His secondary
and Hoescht 33258. FITC fluorescence was not observed without
monensin treatment.
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predominantly necrotic morphology and staining pattern. Glucose
oxidase therefore appears to induce necrosis in HuH7 cells.
Effect of PIF/dermcidin expression on cell survival
Following glucose oxidase treatment, the mean survival of HuH7
cells as assessed by MTT assay was increased from 34 to 43% by
transfection of the PIF/dermcidin-containing vector, a survival
benefit of 26% (Figure 8A). On flow cytometry, forward- and side-
scatter gating demonstrated an increase in live-gated cells from 26
to 37% following PIF/dermcidin transfection, a survival benefit of
42% (Figure 8B). Proteolysis-inducing factor/dermcidin-trans-
fected HuH7 cells did not stain with anti-cleaved caspase 3
antibody. Analysis of the annexin V staining pattern of PIF/
dermcidin-transfected cells demonstrated an increase in the
number of cells staining with annexin only and a decrease in the
number staining with annexin V and PI (Figure 9A). Analysis of
the BOB78 staining pattern of PIF/dermcidin-transfected cells
revealed an increase in the number of cells staining with BOB78
alone and with neither BOB78 nor PI, and a decrease in the
1 2 3 4 5
1 2 3 4 5 6
1 2 3 4 5 6
7 8
387 bp
A
B
C
387 bp
30 kDa
Figure 4 Generation of stable dermcidin transfectants. (A) Dermcidin
PCR. Lane 1 – Untransfected HuH7 cDNA. Lane 2 – Empty vector
transfected HuH7 cDNA. Lane 3 – pcDNA3.1þ PIF transfected HuH7
cDNA. Lane 4 – Blank. Lane 5 – pcDNA3.1þ PIF plasmid. Cells were
cultured under standard conditions and stably transfected using Fugene
with G418 selection. RNA was extracted using Trizol, DNAse treated,
reverse transcribed and amplified by PCR using primers to the coding
region of the PIF cDNA. RNA from the HuH7 cell line was positive for PIF
message only after transfection with pcDNA3.1þ PIF. (B) Dermcidin PCR.
Lane 1 – Empty vector transfected HuH7 cDNA. Lane 2 –
pcDNA3.1þ PIF transfected HuH7 cDNA. Lane 3 – pcDNA3.1þN32Q
transfected HuH7 cDNA. Lane 4 – pcDNA3.1þN44Q transfected HuH7
cDNA. Lane 5 – pcDNA3.1þN32QN44Q transfected HuH7 cDNA.
Lane 6 – untransfected HuH7 cDNA. Lane 7 – Positive control (CF-PAC
cDNA). Lane 8 – Negative control (no cDNA). All transfected cells were
strongly positive for dermcidin expression. Untransfected cells, which had
been maintained in culture for the same period of time, became weakly
positive for expression. (C) Immunoblot for neomycin phosphotransferase
from transfected cells. Lane 1 – Empty vector transfected HuH7 lysate.
Lane 2 – pcDNA3.1þ PIF transfected HuH7 lysate. Lane 3 –
pcDNA3.1þN32Q transfected HuH7 lysate. Lane 4 –
pcDNA3.1þN44Q transfected HuH7 lysate. Lane 5 –
pcDNA3.1þN32QN44Q transfected HuH7 lysate. Lane 6 – untrans-
fected HuH7 lysate. Membranes were probed with a monoclonal antibody
to neomycin phosphotransferase. All transfected cells demonstrated
expression from the pcDNA3.1þ CMV-driven promoter. No expression
was observed in untransfected cells.
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Figure 5 Effect of glucose oxidase on sham-transfected HuH7 cells. (A)
MTT assay. 15 104 cells per well were seeded in 96-well plates, incubated
overnight, then treated with 75 mU ml1 glucose oxidase for 2 h. MTT
uptake by viable cells was assessed by the addition of 50 mg MTT per well
for 4 h. Plates were read at 570 nm following further overnight incubation
with 100 ml per well of 10% SDS, pH 3.0. Glucose oxidase treatment
resulted in a reduction in the viable cell population to 38% of untreated
cells. (B) Gating of live and dead cells by forward- and side-scatter on flow
cytometry. Cells were seeded in six-well plates (1 106 cells per well),
incubated overnight, treated for 2 h with 75 mU ml1 glucose oxidase, then
harvested. Following two washes in PBS, flow cytometry was performed on
a Coulter Epics XL flow cytometer. Treatment with glucose oxidase
resulted in a marked shift in the cell population, increasing mean density and
decreasing size. The resultant populations were subsequently gated as live
and dead. The spread of cells into the dead gate in untreated samples was
constant throughout our experiments, but not observed in untransfected
HuH7s, and was considered to represent an effect of ongoing selection
with G418. (C) Quantification of live and dead gates revealed that GO
treatment resulted in a 65% shift from live to dead gates.
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number of cells staining with both BOB78 and PI (Figure 9B).
These results suggest that dermcidin transfection improves cell
survival by decreasing necrosis, with an increase in both live cells
and cells undergoing apoptosis.
Effect of site-directed mutagenesis of asparagine residues
We substituted glutamine for each of the two asparagine residues
in the PIF/dermcidin polypeptide sequence, both singly and in
combination. When transfected into HuH7 cells, the single
mutations N32Q and N44Q conferred the same survival benefit
as wild-type PIF/dermcidin, as assessed by MTT assay (Figure 8A).
However, on flow cytometry, the N32Q mutation abrogated the
effect on cell survival, whereas the N44Q mutation had no effect
(Figure 8B). Double mutation of N32 and N44 removed the ability
of PIF/dermcidin expression to protect cells as assessed by both
MTT assay and flow cytometry (Figure 8A and B). No significant
difference in the annexin V and BOB78 staining patterns between
N32Q, N44Q and wild-type PIF/dermcidin or N32Q N44Q and
sham transfectants was observed.
DISCUSSION
Previous studies have shown that glucose oxidase induces necrosis
in hepatic cells through the constant generation of H2O2 and
subsequently free oxygen radicals (Lemasters, 1999). In HuH7 cells
we found that cell death occurred almost exclusively by necrosis.
In particular, there was no activation of cleaved caspase 3, a
mediator common to both the receptor-activated and intrinsic
pathways of apoptosis, which is known to be functional in HuH7
cells (Ashkenazi and Dixit, 1998; Feng and Kaplowitz, 2002). The
low level of annexin staining in comparison with double annexin/
PI staining on both flow cytometry and immunocytochemistry was
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Figure 6 Effect of glucose oxidase on annexin V staining of HuH7 cells.
(A) Flow cytometry. Following glucose oxidase treatment, cells were
harvested, washed and stained with annexin V and propidium iodide.
Glucose oxidase increased the proportion of cells staining with annexin
only and with both annexin and PI. (B) Immunocytochemistry. Cells were
seeded at 2 104 per well in eight-well chambered slides, incubated
overnight and treated for 2 h with 75 mU ml1 glucose oxidase. The
medium was then harvested and cytospun on to charged slides at 300 g for
3 min. Cytospins were stained with annexin V and propidium iodide and
visualised using fluorescence microscopy. The majority of cytospun cells had
a necrotic phenotype. However, some showed features of apoptosis
including loss of cytoplasm, blebbing and nuclear condensation (top cell).
Almost all cells co-stained with annexin and PI suggesting any apoptotic
cells had progressed to lose membrane integrity.
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Figure 7 Effect of glucose oxidase on BOB78 staining of HuH7 cells. (A)
Flow cytometry. Following glucose oxidase treatment, cells were harvested,
washed and co-stained with BOB78 antibody at 1/100 in PBS and
propidium iodide. Treatment with glucose oxidase resulted in a decrease in
nonstaining cells and an increase in both BOB78 only and double BOB78
and PI staining. (B) Immunocytochemistry. Cells were seeded at 2 104
per well in eight-well chambered slides, incubated overnight and treated for
2 h with 75 mU ml1 glucose oxidase. The medium was then harvested and
cytospun on to charged slides at 300 g for 3 min. Cytospins were stained
with BOB78 (1/100 in PBS) and propidium iodide and visualised using
fluorescence microscopy. Cytospun cells again demonstrated predomi-
nantly necrotic morphology. A few cells with apoptotic features were seen
(left), but again almost all of these were PI permeable. The pattern of
BOB78 staining was predominantly cytoplasmic in necrotic cells and
showed some redistribution to the plasma membrane in apoptosis,
consistent with our previous findings.
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also consistent with necrotic cell death. In addition, BOB78
expression showed a similar pattern of change to annexin V.
Using the glucose oxidase system, we demonstrated a clear
survival benefit of PIF/dermcidin expression. On MTT assay this
was 26% and on forward- and side-scatter gated flow cytometry,
25%. Shifts from cell apoptosis to necrosis are known to occur in
primary hepatocytes, where the inhibition of caspase activity
converts apoptotic to necrotic cell death in the presence of an
overwhelming death stimulus from staurosporine (Feng and
Kaplowitz, 2002). However, this did not occur in the HuH7 cells,
as cleaved caspase 3 was not activated. In addition, with dermcidin
transfection, the main changes in annexin V staining were a rise in
annexin only and a fall in double annexin/PI staining. This
represents a proportional decrease in necrosis on PIF/dermcidin
expression when considered in light of the MTT assay and
forward- and side-scatter results, which demonstrated that the
population of dead cells is smaller in dermcidin-transfected cells.
The implications of these findings are potentially wide-ranging.
For example, it is possible that during hepatic carcinogenesis
dermcidin expression could improve the ability of cells to survive
in areas of high oxidative stress, resulting in the positive selection
of cells with a survival advantage. Preliminary results suggest that
certain hepatic carcinoma cell lines express dermcidin, and the
development of siRNAs will facilitate investigation of the effects of
inhibiting expression in these cells and in overexpressing HuH7s.
Demonstration of altered expression in hepatic tumours would
confirm the potential of dermcidin to act as an oncogene in
tumours other than breast cancer. Our findings also suggest that
dermcidin could be used to pre-condition nonmalignant hepatic
cells to oxidative stress in a manner similar to other therapies such
as cyclosporin and heat shock (Lemasters et al, 1998). If dermcidin
does play a role in the hepatic response to oxidative stress, its
pattern of expression might be expected to be pericentral, where
hepatocyte cytochrome p450 epxression is high and oxygen
tensions are low, resulting in oxidative stress. The development
of immunohistochemistry and in situ hybridisation will help to
investigate patterns of expression in in vivo models.
As glycosylation appears essential to the ability of PIF to induce
cachexia, we attempted to correlate the ability of dermcidin
expression to promote survival with structural mutations designed
to alter N-glycosylation. This revealed that, although the N44Q
mutation had no effect on survival assessed by either MTT assay or
flow cytometry, the N32Q mutation prevented dermcidin’s pro-
survival effects when assessed by flow cytometry, but not by MTT
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Figure 8 Effect of transfected vector on survival after oxidative stress.
(A) MTT assay. Cells transfected with empty vector (sham transfectants),
wild-type PIF or the N32Q, N44Q or N32Q N44Q mutant forms of PIF
were seeded at 15 104 cells per well in 96-well plates, incubated
overnight, then treated with 75 mU ml1 glucose oxidase for 2 h prior to
MTT assay. Wild-type PIF transfection resulted in a 26% increase in viable
cells following glucose oxidase treatment in comparison with sham
transfection. Transfection with the N32Q and N44Q mutants similarly
protected HuH7 cells from oxidative stress. In contrast, transfection with
the double mutant N32Q N44Q did not bestow a survival benefit. (B)
Flow cytometry.Transfected cells were seeded at 1 106 cells per well in
six-well plates, incubated overnight, treated for 2 h with 75 mU ml1
glucose oxidase, then harvested. Flow-cytometric gating of cells by forward
and side scatter revealed 37% survival of wild-type PIF transfected cells in
comparison with 26% survival of sham transfectants, a survival benefit of
42%. Transfection with the N44Q mutant bestowed a similar benefit to
transfection with wild-type PIF. Neither the N32Q nor the N32Q N44Q
mutants conferred any survival benefit.
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Figure 9 Effect of transfection with wild-type PIF/dermcidin on flow-
cytometric staining patterns of glucose oxidase-treated cells. (A) Annexin
V. Cells were seeded at 1 106 per well, treated with glucose oxidase,
harvested, and stained with annexin V and propidium iodide as before.
Proteolysis-inducing factor transfection resulted in a change in annexinV
only staining from 15 to 22%, PI only staining from 9 to 8%, double staining
from 57 to 54% and no staining from 19 to 16%. (B) BOB78. Cells were
seeded at 1 106 per well, treated with glucose oxidase, harvested, and
stained with BOB78 (1/100 in PBS) and propidium iodide as before. The
proportion of cells staining with BOB78 only increased from 12 to 22% on
PIF transfection. BOB78 and PI double staining decreased from 45 to 27%.
Nonstaining cells increased from 25 to 39% and PI only staining changed
from 19 to 13%.
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assay. As the MTT assay measures cell survival indirectly by
assessing mitochondrial function, this difference suggests that the
N32 residue may mediate a pro-survival effect independent of
mitochondrial function. Dermcidin may subsequently influence
survival via two or more mechanisms. Preconditioning to oxidative
stress by enzymatic induction is well described in hepatic cells, is
active in neuronal cells (in which Y-P30 is protective) (Arthur et al,
2004), and may be one mechanism by which dermcidin acts in
HuH7 cells. Alternatively, expression might protect cells from
oxidative stress by induction of the proteasome system, which is
known to be activated by glycosylated PIF (Smith and Tisdale,
2003; Whitehouse and Tisdale, 2003). Proteasome induction has
been associated with improved survival of both neuronal cells and
liver cells following oxidative stress (Donohue Jr et al, 2004; Lee
et al, 2004). Finally, the fact that double mutation of N32 and N44
contrasted with single N32 mutation in abrogating the survival
effect on MTT assay suggests that a mitochondrial pathway may
also be involved. The mitochondrial permeability transition may
be induced by oxidative stress and is increasingly recognised as an
element of cell necrosis (Lemasters et al, 1998; Lemasters, 1999).
This transition may be blocked by cyclosporin A, an inhibitor of
calcineurin, with which dermcidin shares a homologous phospha-
tase domain (Cunningham et al, 1998; Rusnak and Mertz, 2000),
raising the possibility that this may be the point at which
dermcidin acts on the necrotic pathway.
The structural effects of the asparagine residues which influence
the function of dermcidin have not been determined in the present
study. Several possibilities exist. The motif identified in Y-P30 as
similar to the calcineurin phosphatase domain lies between N32
and N44, and has been demonstrated to have phosphatase activity
(Cunningham et al, 1998, 2000). X-ray crystallography has shown
that asparagine residues contribute to this domain in calcineurin
(Rusnak and Mertz, 2000). It is therefore feasible that loss of both
asparagine residues but not one alone is sufficient to impair such
phosphatase activity. Alternatively, the asparagine residues may be
important in receptor binding, proteolytic processing, or protein
folding or integrity. The receptors for the different products of
dermcidin remain largely uncharacterised, although both high-
and low-affinity receptors on breast cancer cells bind dermcidin
with alkaline phospatase attached to the DCD-1 carboxy-terminus
(Porter et al, 2003) and glycosylated PIF has been suggested to
bind to both hepatocytes and skeletal muscle (Waddell et al,
unpublished observation). Y-P30 has been demonstrated to
interact with calreticulin (Cunningham et al, 2000), although it is
not known whether this also interacts with PIF or DCD-1. It is
therefore possible that asparagine mutagenesis in such a short
sequence might affect dermcidin’s receptor interactions. As polar
amino acids, the hydrophobicity of both asparagine and glutamine
is similarly low (Nozaki and Tanford, 1971) and both have similar
structures. This has resulted in the common use of glutamine for
asparagine substitutions in experiments examining N-glycosyla-
tion, where as little effect as possible on other aspects of protein
structure is desirable. However, due to their low hydrophobicity,
both amino acids are commonly found on the surface of globular
proteins and mutagenesis could therefore have an effect on the
conformation of the short dermcidin peptide, with subsequent
effects on receptor binding or other biological activities. It is also
possible that the substitution may alter proteolytic processing by
rendering a protease target site either more or less accessible. A
subsequent change in the ratios of the different dermcidin
products produced could be expected to alter the biological effect
of expression.
We were unable to demonstrate evidence of N-glycosylation in
the rabbit-reticulocyte lysate in vitro translation system, where
elimination of one or both asparagine residues failed to alter the
molecular weight of translated dermcidin. This contrasts with
previous studies, which have suggested heavy N-glycosylation of
up to 10 kDa, possibly at one site in the 24 kDa moiety (Todorov
et al, 1997), but is consistent with the observation that neither site
represents a typical consensus N-glycosylation sequence, although
N32 has the characteristics of an atypical site (Welply et al, 1983;
Sato et al, 2000). The in vitro translation system was used to
assess dermcidin N-glycosylation, as its immunological analysis is
problematic. The small size of the peptide and its proteolytic
products results in limited antigens to which antibodies may be
developed. Previous studies have used antibodies recognising
epitopes that are glycosylated (Todorov et al, 1996) or involve the
mutated asparagines (Cunningham et al, 1998). However, the use
of radiolabelling in the in vitro translation system avoids these
difficulties and it is well recognised as a model of mammalian
N-glycosylation. The lack of N-glycosylation therefore suggests
that it is not involved in the mediation of survival effects through
dermcidin’s asparagine residues. However, the fact that the system
may not accurately represent glycosylation in HuH7 cells must be
considered.
Whether dermcidin is targeted to the secretory pathway has been
difficult to determine from previous literature. Several in vitro
studies of PIF have used immunological methods of detection and
have always required cell lysates, as opposed to supernatants, for
success (Todorov et al, 1996, 1999). In contrast with these findings,
in vivo studies using the same antibody have demonstrated
glycosylated PIF in urine and suggest that it may be found, bound
to albumin, in serum, suggesting that the molecule may be secreted
(Todorov et al, 1996; Wigmore et al, 2000). The DCD-1 and Y-P30
peptides are secreted, having been identified in sweat and cell
culture medium, respectively (Cunningham et al, 1998; Schittek
et al, 2001). The apparent conflict between this evidence and the
previous in vitro PIF studies may be accounted for by the use of
different antibodies to detect Y-P30, DCD-1 and PIF. The anti-PIF
antibody has been shown to recognise a carbohydrate epitope
(Todorov et al, 1997) and it is feasible that, when glycosylated, the
peptide is not secreted and requires cell lysis for release. We have
demonstrated that the dermcidin signal peptide is cleaved and that
inhibition of protein transport is required to detect dermcidin in
HuH7s, supporting secretion in these cells. However, as the V5-His
tag was attached to the carboxy-terminus, if dermcidin is
proteolytically processed, only DCD-1 may be labelled and there-
fore we cannot comment on whether Y-P30 or PIF are secreted
or even produced by these cells. Further studies of the antigen
specificity of the different anti-PIF/dermcidin antibodies and
careful analysis of glycosylation in different cell types will be
required to address these issues using immunological methods.
Our results complete the cloning of PIF, Y-P30 and dermcidin,
confirming that they arise from the same polypeptide, cDNA, and
gene, dermcidin. No other sequence in the human genome shows
homology on BLAST searching. Why such diverse functions
should have evolved in products of the same gene is unclear.
Proteolysis-inducing factor was originally purified from a murine
tumour (MAC 16) and would therefore be expected to have a
murine homologue. However, although partial synteny between
the coding sequence for the N-terminus of PIF and a sequence on
murine chromosome 15 has been found, a full match does not
appear to exist. This may reflect strain variations in the mouse
genome database, which was developed from the C57BL/6J strain.
Additional sequences with homology to the dermcidin sequence
are present in the genome of the chimpanzee Pan troglodytes,
Rattus norvegicus and caenorhabditis elegans (genbank accession
numbers NM_173108/AF531422 and AC024770, respectively), but
have as yet to be located in the zebrafish genome. The PIF/
dermcidin coding sequence therefore appears to demonstrate
evolutionary conservation, suggesting that the gene may have an
important cellular function. Several features of the dermidin cDNA
suggest that production of its various products may be regulated
at the post-transcriptional or post-translational levels. Firstly,
there are no alternative start sites in the sequence. Secondly, the
sequence of Y-P30 can be directly deduced from continuous exons
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and the cleavage site of the signal peptide is encoded entirely by
exon 1, suggesting that they are not products of differential
splicing. It is therefore likely that differential proteolysis is
responsible for the production of the different dermcidin peptides
and in sweat, four different peptides have been identified, which
appear to be proteolytic products (Flad et al, 2002). The specific
proteases involved remain to be determined. Thirdly, PIF shares
the same core peptide sequence as Y-P30, but is highly glyco-
sylated (Todorov et al, 1997).
We have demonstrated that the survival effect of dermcidin,
potentially mediated via the calcineurin-like phosphatase domain,
is active in cells known to respond to glycosylated PIF. Post-
translational modification is almost certainly required for the
cachexia-inducing effects demonstrated by Todorov et al (1996)
and the abnormal glycosylation known to occur in neoplasia may
prove to be the mechanism by which this occurs. Further studies
of expression, structure and post-translational modification have
great potential to characterise further the functions of products
of this gene.
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